SCHEMBL2903472

SCHEMBL2903472

O=C(O)c1ccc(S(=O)(=O)Nc2ccccc2Sc2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
SLC16A3 O15427 2/20 0.52
MAPT P10636 3/20 0.52
HPGD P15428 2/20 0.52
TDP1 Q9NUW8 2/20 0.51
POLB P06746 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
STAT3 P40763 1/20 0.50
EP300 Q09472 1/20 0.50
GAA P10253 1/20 0.49
GFER P55789 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
GLA P06280 1/20 0.49
PTPN1 P18031 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3756565 0.89 POLB (0.57) ALDH1A1SMN1; SMN2MAPTHPGDTDP1
SCHEMBL2903213 0.84 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2MAPTHPGDTDP1
SCHEMBL21786249 0.83 LMNA (0.60) ALDH1A1SMN1; SMN2MAPTTDP1POLB
SCHEMBL7674914 0.78 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2GAANPSR1MEN1
SCHEMBL16127963 0.78 ALDH1A1 (0.69) ALDH1A1SLC16A3HPGDTDP1POLB
SCHEMBL2897478 0.78 NPC1 (0.50) ALDH1A1SMN1; SMN2MAPTHPGDTDP1
SCHEMBL3050268 0.75 MCOLN3 (0.68) ALDH1A1SMN1; SMN2SLC16A3MAPTTDP1
SCHEMBL3043992 0.75 PTPN1 (0.63) SLC16A3MAPTPOLBGAAGFER
SCHEMBL3047861 0.75 MEN1 (0.66) ALDH1A1SLC16A3STAT3EP300PTPN1
SCHEMBL3041146 0.74 BDKRB1 (0.70) ALDH1A1SLC16A3HPGDPOLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298299-A1 NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-11-25 US disclosed
EP-2215055-A1 NEW NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS Richter Gedeon Nyrt. (HU) 2010-08-11 EP disclosed
WO-2009053763-A1 NEW NON-PEPTIDE DERIVATIVES AS BRADYKININ BL ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298299-A1 NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS BDKRB1, BDKRB2, NPBWR1 ALDH1A1 4439/4885SMN1; SMN2 4628/4885SLC16A3 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.